Session » Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)

Date: Saturday, November 6, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 0196

A Single Center, Double Blind, Randomized, Placebo-Controlled Trial of Anakinra in Adult Patients with Features of Cytokine Storm Syndrome in COVID-19

8:30AM-10:30AM: Abstract Number: 0205

An Observational Study from the Perspective of Rheumatology in the Management of Patients with Psoriatic Arthritis in Turkey – LOOP Study

8:30AM-10:30AM: Abstract Number: 0201

Australian Psoriatic Arthritis (PsA) Biologic Disease-modifying Antirheumatic Drug (bDMARD) Treatment Pathways Using Sankey Diagrams and Predictive Analysis: A Combined Australian Rheumatology Association Database (ARAD) and Pharmaceutical Benefits Scheme (PBS) Analysis

8:30AM-10:30AM: Abstract Number: 0203

Chemoprophylaxis in Latent Tuberculosis Associated with Rheumatic Immune-mediated Diseases. Study of 240 Patients from a Single University Hospital

8:30AM-10:30AM: Abstract Number: 0186

Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases: Data from INBUILD-ON

8:30AM-10:30AM: Abstract Number: 0188

Effect of Nintedanib on Categorical Changes in FVC in Patients with Progressive Fibrosing ILDs: Further Analyses of the INBUILD Trial

8:30AM-10:30AM: Abstract Number: 0183

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Results from the Phase 3, Randomized, Double-blind Clinical Trial for CsDMARD-IR and Bio-IR Patients

8:30AM-10:30AM: Abstract Number: 0194

Eye Opening: Use of IL-6 Inhibition in Non-Paraneoplastic Autoimmune Retinopathy

8:30AM-10:30AM: Abstract Number: 0198

High Dose Intravenous Methylprednisolone Induces Rapid Improvement of Visual Acuity in Non-Infectious Uveitis of Different Immune Mediated Inflammatory Diseases

8:30AM-10:30AM: Abstract Number: 0206

Hydroxycloroquine-Induced Atrioventricular Block in Inmune-Mediated Diseases. Single University Center Study of 293 Patients

8:30AM-10:30AM: Abstract Number: 0209

IgG4 Related Disease: Response to Immunosuppressive Therapy – A Single Centre Retrospective Study in the United Kingdom

8:30AM-10:30AM: Abstract Number: 0200

In Undifferentiated Arthritis, DMARD-treatment Intensified During the Last Decennia but Did Not Result in Improved Outcomes

8:30AM-10:30AM: Abstract Number: 0192

Influence of Canakinumab Dosing on Efficacy and Safety of Long-term Treatment in Patients with Familial Mediterranean Fever – Interim Analysis of the RELIANCE Registry

8:30AM-10:30AM: Abstract Number: 0191

Influence of Canakinumab Dosing on Long-term Efficacy and Safety in Patients with Cryopyrin-associated Periodic Syndromes (CAPS) – 30-months Interim Analysis of the RELIANCE Registry

8:30AM-10:30AM: Abstract Number: 0195

JAK Inhibitors in Refractory Adult and Childhood-Onset Still’s Disease

8:30AM-10:30AM: Abstract Number: 0190

Long-term Safety of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes – Interim Analysis of the RELIANCE Registry

8:30AM-10:30AM: Abstract Number: 0208

Musculoskeletal Immune-Related Adverse Effects of Immune Checkpoint Inhibitors at a Single Site in a Hispanic Population in Puerto Rico

8:30AM-10:30AM: Abstract Number: 0185

Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects

8:30AM-10:30AM: Abstract Number: 0184

Phase III, Randomized Trial Comparing Clinical Outcomes Between Patients with Moderate-to-severe Chronic Plaque Psoriasis Receiving Adalimumab Reference Product (RP) Continuously versus Those Who Switched Between BI 695501 and Adalimumab RP

8:30AM-10:30AM: Abstract Number: 0199

Rapid Improvement in Cystoid Macular Edema with High Dose Intravenous Methylprednisolone in Non-Infectious Uveitis of Different Immune Mediated Inflammatory Diseases

8:30AM-10:30AM: Abstract Number: 0204

Risk of Hepatitis B Virus Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics After Prophylactic Anti-viral Agents

8:30AM-10:30AM: Abstract Number: 0187

Safety and Tolerability of Nintedanib in Patients with Autoimmune Disease-Related Interstitial Lung Diseases: Pooled Data from the SENSCIS and INBUILD Trials

8:30AM-10:30AM: Abstract Number: 0197

Successful Treatment of Severe COVID-19 Pneumonia with Simultaneous Tocilizumab and Anakinra – A Case Series

8:30AM-10:30AM: Abstract Number: 0189

Tapering and Discontinuation of Background Therapies During the Transition to Rilonacept Monotherapy in RHAPSODY, a Phase 3 Clinical Trial of Rilonacept in Patients with Recurrent Pericarditis

8:30AM-10:30AM: Abstract Number: 0193

Tocilizumab for the Treatment of Familial Mediterranean Fever – a Randomized, Double Blind, Placebo-controlled Phase II Study

8:30AM-10:30AM: Abstract Number: 0207

Treatment of Ocular Sarcoidosis: Study of 65 Patients of a Series of 384 Patients from a Single University Hospital

8:30AM-10:30AM: Abstract Number: 0202

Variables Associated with Response to Therapy in Patients with Interstitial Pneumonia with Autoimmune Features

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].